Caption Management, LLC Prothena Corp Public LTD CO Call Options Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $623,583 - $1.01 Million	-19,300 Reduced 30.2%	44,600 $1.62 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $2.32 Million - $3.46 Million	49,000 Added 328.86%	63,900 $3.08 Million
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $719,074 - $1.17 Million	14,900 New	14,900 $1.02 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $1.82 Million - $2.28 Million	35,000 New	35,000 $2.11 Million
Q3 2021 Nov 12, 2021	SELL	$48.2 - $78.89 $1.45 Million - $2.37 Million	-30,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $432,600 - $1.15 Million	20,000 Added 200.0%	30,000 $1.54 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $110,000 - $282,400	10,000 New	10,000 $252,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $678M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.